Syndax Pharmaceuticals Inc SNDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SNDX is a good fit for your portfolio.
News
-
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
-
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
-
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
-
Syndax Says Revumenib NDA Granted FDA Priority Review
-
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
-
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
-
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $21.72
- Day Range
- $21.48–21.94
- 52-Week Range
- $11.22–25.34
- Bid/Ask
- $21.14 / $34.37
- Market Cap
- $1.84 Bil
- Volume/Avg
- 1.0 Mil / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 184
- Website
- https://www.syndax.com
Comparables
Valuation
|
Metric
|
SNDX
|
CLDX
|
FUSN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.52 | 5.10 | 7.65 |
Price/Sales | — | 275.86 | 677.85 |
Price/Cash Flow | — | — | — |
Price/Earnings
SNDX
CLDX
FUSN
Financial Strength
|
Metric
|
SNDX
|
CLDX
|
FUSN
|
|---|---|---|---|
Quick Ratio | 9.96 | 13.69 | 14.66 |
Current Ratio | 10.00 | 13.87 | 15.01 |
Interest Coverage | −1,107.28 | — | −19.06 |
Quick Ratio
SNDX
CLDX
FUSN
Profitability
|
Metric
|
SNDX
|
CLDX
|
FUSN
|
|---|---|---|---|
Return on Assets (Normalized) | −37.16% | −30.49% | −33.14% |
Return on Equity (Normalized) | −40.25% | −33.19% | −43.87% |
Return on Invested Capital (Normalized) | −44.82% | −32.85% | −36.42% |
Return on Assets
SNDX
CLDX
FUSN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rymwhccrm | Mxgmf | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jgkqdjmz | Vdqfwwm | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hpdmjfrd | Smqdykc | $98.6 Bil | |
MRNA
| Moderna Inc | Hjhnxst | Ggpfs | $41.0 Bil | |
ARGX
| argenx SE ADR | Tcyvngwgn | Tmkbs | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Cbtnxnsb | Glv | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xhycrkht | Vlmdx | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zrkznzk | Llxlbt | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pshvrfbmky | Vlzpsn | $12.6 Bil | |
INCY
| Incyte Corp | Mbhwcbwc | Mftphpz | $12.0 Bil |